Promising prognostic value of Transglutaminase type 2 and its correlation with tumor-infiltrating immune cells in skin cutaneous melanoma

• Published in: Cell death discovery Vol. 8; no. 1; p. 294
• Main Authors: Muccioli, Silvia, Ciaccio, Roberto, Brillo, Valentina, Leanza, Luigi
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 20-06-2022; Springer Nature B.V; Nature Publishing Group
• Subjects: 631/250/580; 631/67/1813/1634; Apoptosis; Biochemistry; Biomedical and Life Sciences; Cancer; Cell Biology; Cell Cycle Analysis; Immune response; Immunotherapy; Life Sciences; Medical prognosis; Melanoma; mRNA; Patients; Phenotypes; Stem Cells; Transglutaminase 2; Tumor microenvironment; Tumor-infiltrating lymphocytes; Tumorigenesis
• ISSN: 2058-7716; 2058-7716
• DOI: 10.1038/s41420-022-01087-1

Tissue Transglutaminases (TGs) are crosslinking enzymes with pleiotropic functions that have been linked to the development and progression of numerous cancers, with a recent focus on their ability to remodel the tumor microenvironment. Although several pieces of evidence demonstrated their importance in the regulation of the major signaling pathways that control oncogenesis, the correlation between TGs with clinical and pathological features remains controversial and to be further explored. Moreover, an assessment of the TGs alterations together with a functional analysis associated with clinical features and prognostic values are still lacking and would help to understand these intricacies, particularly in human cancers. In the present study, we processed data from numerous public datasets to investigate TGs distribution and prognostic signature in cancer patients. Here, we found that skin cutaneous melanoma (SKCM) shows the highest abundance of TGs mutations among the other human cancers. Interestingly, among all the TGs, TG2 is the only member whose expression is associated with a better overall survival in SKCM, although its expression increases with the worsening of the tumor phenotype. Our analysis revealed a strong positive association between TG2 expression and anti-tumoral immune response, which would explain the relationship between high mRNA levels and better overall survival. Our data suggest that TG2 may be presented as a new promising immune biomarker of prognosis in SKCM, which may contribute to identifying patients who would benefit the most from adjuvant immunotherapy.